IVAX nose the score

Published: 4-Nov-2005

IVAX, Miami, Florida, US, has received final Mutual Recognition Procedure (MRP) approval from the MHRA for Fluticasone nasal spray in 11 countries across Europe.


IVAX, Miami, Florida, US, has received final Mutual Recognition Procedure (MRP) approval from the MHRA for Fluticasone nasal spray in 11 countries across Europe.

It is expected that this approval will be followed by national marketing authorisation and launch in each of the 11 countries over the next few months.

Fluticasone is the generic equivalent of Flixonase (known in the US as Flonase), which is marketed by GlaxoSmithKline for the treatment of rhinitis. There are no other known generic alternatives presently marketed in Europe.

The spray has already been approved in the UK, where it was launched in May, and has an ANDA (Abbreviated New Drug Application) pending with the US FDA.

You may also like